PARP inhibitors for hereditary breast cancer with germline BRCA mutation

被引：0
|
作者：
Im, Seock-Ah [1 ]
机构：
[1] Seoul Natl Univ, Canc Res Inst, Dept Internal Med, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.426
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PSY8-3
引用
收藏
页码：S423 / S423
页数：1
相关论文
共 50 条
  • [31] Evidence of intratumoral stem cells in breast cancer patients with BRCA germline mutation
    Singer, C. F.
    Zabkova, P.
    Pfeiler, G.
    Gschwantler-Kaulich, D.
    Fink-Retter, A.
    Staudigl, C.
    Walter, I
    Hudelist, G.
    Spiess, A. C.
    Kubista, E.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2009, 69 (08) : 761 - 761
  • [32] GERMLINE MUTATION OF BRCA1 IN JAPANESE BREAST-CANCER FAMILIES
    INOUE, R
    FUKUTOMI, T
    USHIJIMA, T
    MATSUMOTO, Y
    SUGIMURA, T
    NAGAO, M
    CANCER RESEARCH, 1995, 55 (16) : 3521 - 3524
  • [33] Outcome of patients with breast cancer and a germline BRCA mutation in a prospective cohort.
    Arun, Banu
    Barrera, Angelica Gutierrez
    Layman, Rachel M.
    Gruschkus, Stephen K.
    Bedrosian, Isabelle
    Albarracin, Constance T.
    Barcenas, Carlos Hernando
    Valero, Vicente
    Litton, Jennifer Keating
    Tripathy, Debu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update
    Tung, Nadine M.
    Zakalik, Dana
    Somerfield, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (26) : 2959 - +
  • [35] Characteristics and clinical outcome of BRCA germline mutation carriers with advanced breast cancer treated with PARP (poly ADP-ribose polymerase) inhibitors: A single institution experience.
    Mustafayev, Fatma Nihan Akkoc
    Munsell, Mark
    Gutierrez-Barrera, Angelica M.
    Yam, Clinton
    Layman, Rachel M.
    Arun, Banu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] PARP inhibitors in cancer: moving beyond BRCA
    Telli, Melinda L.
    LANCET ONCOLOGY, 2011, 12 (09): : 827 - 828
  • [37] Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients
    Verhoog, LC
    Berns, EMJJ
    Brekelmans, CTM
    Seynaeve, C
    Meijers-Heijboer, EJ
    Klijn, JGM
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (21) : 119S - 124S
  • [38] BRCA1 germline mutations in Chinese patients with hereditary breast and ovarian cancer
    Li, N
    Zhang, X
    Cai, Y
    Xu, X
    Zhang, L
    Pan, KF
    Wu, LY
    Wang, MR
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 : 172 - 178
  • [39] Evaluating chemotherapy receipt and candidacy for PARP inhibitors in germline BRCA1/2 carriers with early and locally advanced breast cancer
    Wong, Stephanie
    Apostolova, Carla
    Ferroum, Amina
    Alhassan, Basmah
    Prakash, Ipshita
    Basik, Mark
    Martel, Karyne
    Meterissian, Sarkis
    Fleiszer, David
    Wong, Nora
    Malagon, Talia
    Foulkes, William
    Boileau, Jean-Francois
    CANCER RESEARCH, 2024, 84 (09)
  • [40] Beyond breast and ovarian cancers: PARP BRCA mutation-associated and BRCA-like inhibitors for solid tumors
    O'Sullivan, Clara C.
    Moon, Dominic H.
    Kohn, Elise C.
    Lee, Jung-Mim
    FRONTIERS IN ONCOLOGY, 2014, 4
12345